Exozymes (EXOZ) Operating Income (2023 - 2026)
Exozymes (EXOZ) posted quarterly Operating Income of -$2.7 million for Q4 2025, down 35.91% year-over-year from -$4.2 million in Q4 2024, and down 6.87% quarter-over-quarter from -$2.5 million in Q3 2025.
Exozymes (EXOZ) Operating Income (2023 - 2026) Analysis & Trends
Exozymes (EXOZ) has reported Operating Income for 3 consecutive years, with -$2.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Income fell 35.91% year-over-year to -$2.7 million; the TTM figure through Dec 2025 stood at -$9.7 million (down 63.79% YoY), while the FY2025 annual figure was -$9.7 million, down 63.79% from the prior year.
- Operating Income fell to -$2.7 million in Q4 2025 per EXOZ's latest filing, from -$2.5 million in the prior quarter.
- Across five years, Operating Income topped out at -$391846.0 in Q3 2023 and bottomed at -$2.7 million in Q4 2025.
- Historically, Operating Income has averaged -$1.7 million across 3 years, with a median of -$1.8 million in 2024.
- Annual changes were most pronounced in 2024 — Operating Income plunged 311.32% — and 2025, when it slumped 35.91%.
- Exozymes' Operating Income stood at -$985047.0 in 2023, then plunged by 101.34% to -$2.0 million in 2024, then tumbled by 35.91% to -$2.7 million in 2025.
- Business Quant data shows EXOZ's Operating Income at -$2.7 million in Q4 2025, -$2.5 million in Q3 2025, and -$2.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 133.12 Mn |
| 10 | Exozymes | 64.09 Mn | 64.09 Mn | - | -2.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.95 Mn |
| Dec 31, 2025 | -2.70 Mn |
| Sep 30, 2025 | -2.52 Mn |
| Jun 30, 2025 | -2.55 Mn |
| Mar 31, 2025 | -1.95 Mn |
| Dec 31, 2024 | -1.98 Mn |
| Sep 30, 2024 | -1.61 Mn |
| Jun 30, 2024 | -1.33 Mn |
| Mar 31, 2024 | -1.01 Mn |
| Dec 31, 2023 | -985,047.00 |
| Sep 30, 2023 | -391,846.00 |